KemPharm, Inc. (NASDAQ:KMPH – Get Rating) was the target of a significant increase in short interest during the month of December. As of December 30th, there was short interest totalling 1,630,000 shares, an increase of 5.2% from the December 15th total of 1,550,000 shares. Currently, 5.2% of the company's stock are sold short. Based on an average trading volume of 208,300 shares, the days-to-cover ratio is presently 7.8 days.

Insider Transactions at KemPharm

In other news, CEO Richard W. Pascoe acquired 9,500 shares of the stock in a transaction that occurred on Friday, January 13th. The stock was purchased at an average cost of $5.44 per share, with a total value of $51,680.00. Following the completion of the acquisition, the chief executive officer now directly owns 19,973 shares in the company, valued at $108,653.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.10% of the company's stock.

Hedge Funds Weigh In On KemPharm

Several institutional investors and hedge funds have recently bought and sold shares of KMPH. Laurion Capital Management LP acquired a new stake in shares of KemPharm during the 2nd quarter valued at about $2,597,000. Janney Montgomery Scott LLC lifted its holdings in shares of KemPharm by 36.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 479,220 shares of the specialty pharmaceutical company's stock valued at $2,166,000 after buying an additional 129,100 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of KemPharm during the 1st quarter valued at about $114,000. JPMorgan Chase & Co. lifted its holdings in shares of KemPharm by 28.3% during the 1st quarter. JPMorgan Chase & Co. now owns 18,095 shares of the specialty pharmaceutical company's stock valued at $91,000 after buying an additional 3,990 shares during the last quarter. Finally, Kingsview Wealth Management LLC acquired a new stake in shares of KemPharm during the 2nd quarter valued at about $54,000. Hedge funds and other institutional investors own 19.39% of the company's stock.

KemPharm Trading Down 10.5 %

KemPharm (NASDAQ:KMPH – Get Rating) last released its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). KemPharm had a negative return on equity of 16.12% and a negative net margin of 328.56%. The company had revenue of $2.87 million for the quarter, compared to analysts' expectations of $2.97 million. On average, analysts expect that KemPharm will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. StockNews.com upgraded KemPharm from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. Cantor Fitzgerald assumed coverage on KemPharm in a report on Thursday, November 17th. They set an "overweight" rating and a $20.00 target price on the stock. Finally, Canaccord Genuity Group lowered their target price on KemPharm from $20.00 to $19.00 in a report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.25.

KemPharm Company Profile

(Get Rating)

KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.

Recommended Stories

• Get a free copy of the StockNews.com research report on KemPharm (KMPH)
• EVgo Stock is Charged Up to Ride the EV Adoption Wave
• Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
• High-Yield, Deep-Value Verizon Puts In A Bottom
• Should You Bet Against The Nasdaq 100 With This Inverse ETF?
• Can Coty Stock Emerge in 2023 With Upside

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.